• 提示：详情请下载说明书。

• 产品描述： Adoprazine (SLV313) is a full 5-HT1A receptor agonist with a pEC50 of 9 at cloned h5-HT1A receptors. Adoprazine (SLV313) is a full D2 and D3 receptor antagonist with pA2s of 9.3 and 8.9 at hD2 and hD3 receptors, respectively. Adoprazine (SLV313) has the characteristics of atypical antipsychotics.

• 靶点： 5-HT1A Receptor:9 (pEC50);D2 Receptor:9.3 (pA2);D3 Receptor:8.9 (pA2);D4 Receptor:8.0 (pKi);5-HT7 Receptor:7.2 (pKi);5-HT1A Receptor;9.1 (pKi);D2 Receptor:8.4 (pKi);D3 Receptor:8.4 (pKi);Others

• 体内研究：
  Adoprazine (SLV313) (0.1-10 mg/kg; p.o.; single) is sufficient to reduce extracellular 5-HT and increase dopamine levels in the nucleus accumbens in a dose- and time-dependent manner Animal Model: Male Wistar rats (275-350 g) Dosage: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg Administration: p.o.; single Result: Led to a dose- and time-dependent increase in extracellular levels of DA, DOPAC, and HVA. In contrast, led to a reduction in 5-HT levels and no change in 5-HIAA levels.

• 参考文献：
  1. Andrew C McCreary, et al. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsych 2. Liesbeth A Bruins Slot, et al. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol. 2006 Mar 18;534(1-3):63-70.

• 溶解性： Soluble  in  DMSO

• 保存条件： -20℃

• 配置溶液浓度参考：
  

  	1mg	5mg	10mg
  1 mM	2.466 ml	12.332 ml	24.663 ml
  5 mM	0.493 ml	2.466 ml	4.933 ml
  10 mM	0.247 ml	1.233 ml	2.466 ml
  50 mM	0.049 ml	0.247 ml	0.493 ml

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *